{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:44:43Z","timestamp":1793051083908,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to evaluate early pulmonary function changes after stereotactic body radiotherapy (SBRT) in patients with lung oligometastases and to identify predictors of clinically meaningful decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective analysis included 55 patients with 71 lung metastases treated with SBRT between January 2021 and October 2024. Pulmonary function tests (PFTs) were performed before and three months after treatment. Parameters included forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1\/FVC ratio, vital capacity (VC), and diffusing capacity of the lungs for carbon monoxide (DLCO). A decline of \u226510% from baseline was considered clinically meaningful. Cut-off values were determined by receiver operating characteristic (ROC) analysis. Associations were evaluated using Chi-square tests. Overall survival (OS) was analyzed with the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean FEV1 declined from 82.5 \u00b1 22.8% to 78.3 \u00b1 21.2% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007), and the FEV1\/FVC (% of predicted ratio) decreased from 110.3 \u00b1 14.1% to 106.8 \u00b1 16.2% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04). No significant change was observed in FVC, VC, or DLCO. A \u226510% decline in FEV1 was observed in 23.6% of patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13), and in the FEV1\/FVC ratio in 18.1% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10). Clinically meaningful declines were significantly associated with non-small cell lung cancer (NSCLC) histology (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), leukocyte count \u22657.18 \u00d710\u2265\/\u03bcL (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), metastasis diameter \u226512.5 mm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), and age \u226565 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). PFT change was not associated with OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SBRT in patients with lung oligometastases results in modest early declines in airflow parameters, while lung volumes and gas exchange remain stable. NSCLC histology, systemic inflammation, metastasis size, and age may help identify patients at higher risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2018_25","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:06:37Z","timestamp":1774875997000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Early changes in pulmonary function after stereotactic body radiotherapy for lung oligometastases"],"prefix":"10.4103","volume":"22","author":[{"given":"Rahmi A.","family":"Aksoy","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Izmir City Hospital, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Koca","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmeyye","family":"\u00c7\u0131tak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya","family":"Dirol","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin F.","family":"Korcum","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"R1-20260331","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"R2-20260331","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thoraxjnl-2013-204528","article-title":"Pulmonary metastasectomy: What is the practice and where is the evidence for effectiveness?","volume":"69","author":"Treasure","year":"2014","journal-title":"Thora\u00d7"},{"key":"R3-20260331","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"R4-20260331","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"R5-20260331","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2020.01.010","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure","volume":"145","author":"Pasalic","year":"2020","journal-title":"Radiother Oncol"},{"key":"R6-20260331","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and \u0131mmunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20260331","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/JTO.0b013e31824165d7","article-title":"Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?","volume":"7","author":"Guckenberger","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R8-20260331","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijrobp.2023.04.009","article-title":"Comparison of changes in pulmonary function after stereotactic body radiation therapy versus conventional 3-dimensional conformal radiation therapy for Stage I and IIA non-small cell lung cancer: An analysis of the TROG 09.02 (CHISEL) phase 3 trial","volume":"117","author":"Bucknell","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20260331","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0b013e3181a99ff6","article-title":"Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients","volume":"4","author":"Stephans","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R10-20260331","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jrr\/rraa131","article-title":"Changes in pulmonary function and their correlation with dose-volume parameters in patients undergoing stereotactic body radiotherapy for lung cancer","volume":"62","author":"Takemoto","year":"2021","journal-title":"J Radiat Res"},{"key":"R11-20260331","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ijrobp.2023.09.052","article-title":"Impact on pulmonary function in a randomized trial of single-fraction and multifraction stereotactic body radiation therapy for pulmonary oligometastatic disease: An analysis of TROG 13.01 (SAFRON II)","volume":"118","author":"Bucknell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20260331","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"R13-20260331","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.05.00034505","article-title":"General considerations for lung function testing","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"R14-20260331","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"R15-20260331","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.athoracsur.2016.01.069","article-title":"Impact of sublobar resection on pulmonary function: Long-term results from American College of Surgeons Oncology Group Z4032 (Alliance)","volume":"102","author":"Kent","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"R16-20260331","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13019-018-0773-y","article-title":"Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: Results of a prospective multicenter phase II trial","volume":"13","author":"Palussi\u00e8re","year":"2018","journal-title":"J Cardiothorac Surg"},{"key":"R17-20260331","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijrobp.2007.12.051","article-title":"Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer","volume":"72","author":"Henderson","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20260331","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2012.09.016","article-title":"Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer","volume":"85","author":"Guckenberger","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5 Suppl","key":"R19-20260331","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.12-2345","article-title":"Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Alberg","year":"2013","journal-title":"Chest"},{"key":"R20-20260331","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5603\/FM.a2017.0101","article-title":"Elevated leukocyte count as a harbinger of systemic inflammation, disease progression, and poor prognosis: A review","volume":"77","author":"Chmielewski","year":"2018","journal-title":"Folia Morphol (Warsz)"},{"key":"R21-20260331","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/biomedicines9091181","article-title":"Promising biomarkers of radiation-\u0131nduced lung \u0131njury: A review","volume":"9","author":"Liu","year":"2021","journal-title":"Biomedicines"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2018_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:45:18Z","timestamp":1787838318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2018_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2018_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}